Senhwa Biosciences Inc (6492):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Senhwa Biosciences Inc (6492) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8286
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:台湾
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Senhwa Biosciences Inc (Senhwa) is a clinical stage drug development company that develops next generation DNA damage response drugs for the treatment of cancer. The company’s pipeline products include CX-5461 and CX-4945. Its CX-5461, a G4-stabilizing compound, is a Pol I inhibitor that triggers the p53 pathway by causing nucleolar stress, and is being evaluated in the treatment of hematological malignancies, ovarian cancer, solid tumors and breast cancers. Senhwa’s CX-4945 is a small molecule CK2 inhibitor that prevents DNA break repair, and results in cancer cell death as a combination therapy. It collaborates with global investigators and service providers to develop its pipeline products. The company has operations in Taiwan and the US. Senhwa is headquartered in New Taipei City, Taiwan.

Senhwa Biosciences Inc (6492) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Senhwa Biosciences Acquires Assets Related To Cancer Treatment Programs From Cylene Pharma 10
Venture Financing 11
Senhwa Biosciences Raises USD0.9 Million in Venture Financing 11
Senhwa Biosciences Raises US$17 Million In Series B Financing Round 12
Senhwa Biosciences Raises USD0.8 Million in Venture Financing 13
Senhwa Biosciences Raises USD11.6 Million in Venture Financing 14
Partnerships 15
Senhwa Biosciences Enters into Agreement with Pediatric Brain Tumor Consortium 15
Senhwa Biosciences Enters into Agreement with Canadian Cancer Trials 16
Licensing Agreements 17
Senhwa Biosciences Enters into Licensing Agreement with Chaperone Therapeutics 17
Equity Offering 18
Senhwa Biosciences Raises USD45.5 Million in IPO 18
Senhwa Biosciences Inc – Key Competitors 19
Senhwa Biosciences Inc – Key Employees 20
Senhwa Biosciences Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Corporate Communications 22
Feb 07, 2017: Senhwa biosciences appoints John Soong as chief medical officer 22
Product News 23
11/17/2017: Senhwa Won the National Innovation Award with Novelty of CX-5461 23
09/19/2017: Senhwa CX-5461 in line with the Trend of DDR Mechanism in Anticancer Drug Development 24
06/17/2017: Senhwa CX-5461 has the potential to obtain accelerated approval for multiple indications with common biomarker 25
06/08/2017: New leukemia treatment outperforms standard chemotherapies 26
Product Approvals 27
Jan 04, 2017: Senhwa Biosciences CX-4945 Granted Orphan Drug Designation by the US FDA in Cholangiocarcinoma 27
Clinical Trials 28
Dec 12, 2017: Senhwa Announces the Result of phase I Data of CX-5461 in the Treatment of Hematological Malignancies 28
Oct 16, 2017: Senhwa CX-5461 Phase I Data of Hematological Malignancies was Accepted and will be Published at the 59th ASH Annual Meeting 29
Other Significant Developments 30
Sep 07, 2017: Senhwa Biosciences: Notice of US subsidiary changes corporate name 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Senhwa Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Senhwa Biosciences Acquires Assets Related To Cancer Treatment Programs From Cylene Pharma 10
Senhwa Biosciences Raises USD0.9 Million in Venture Financing 11
Senhwa Biosciences Raises US$17 Million In Series B Financing Round 12
Senhwa Biosciences Raises USD0.8 Million in Venture Financing 13
Senhwa Biosciences Raises USD11.6 Million in Venture Financing 14
Senhwa Biosciences Enters into Agreement with Pediatric Brain Tumor Consortium 15
Senhwa Biosciences Enters into Agreement with Canadian Cancer Trials 16
Senhwa Biosciences Enters into Licensing Agreement with Chaperone Therapeutics 17
Senhwa Biosciences Raises USD45.5 Million in IPO 18
Senhwa Biosciences Inc, Key Competitors 19
Senhwa Biosciences Inc, Key Employees 20
Senhwa Biosciences Inc, Subsidiaries 21

List of Figures
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Senhwa Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Senhwa Biosciences Inc (6492):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AbbVie Inc (ABBV):企業の財務・戦略的SWOT分析
    AbbVie Inc (ABBV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Varian Medical Systems, Inc.:戦略・SWOT・企業財務分析
    Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report Summary Varian Medical Systems, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Cyteir Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cyteir Therapeutics Inc (Cyteir Therapeutics) discovers, develops and commercializes synthetic lethal therapeutics for the treatment of cancer and autoimmune disease. It specializes in the development of small molecules that targets RAD51 to induce synthetic lethality in diseases with a gain …
  • Devon Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Devon Energy Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Devon Energy Corp (Devon Energy) is an independent energy company. The company carries out exploration, development, and production of oil, natural gas and natural gas liquids (NGLs). It has its op …
  • Spectral Medical Inc (EDT):企業の財務・戦略的SWOT分析
    Summary Spectral Medical Inc (Spectral), formerly Spectral Diagnostics Inc, is a biotechnology company that develops and commercializes diagnostic solutions for patient management. The company’s products comprise EAA, PMX, SAMI, toraymyxin and reagents. Its EAA is an endotoxin activity assay, which …
  • Amicus Therapeutics Inc (FOLD):企業の財務・戦略的SWOT分析
    Amicus Therapeutics Inc (FOLD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Premera Blue Cross:企業の戦略的SWOT分析
    Premera Blue Cross - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Statnett SF:企業の戦略的SWOT分析
    Statnett SF - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Bukwang Pharm Co Ltd (003000)-製薬・医療分野:企業M&A・提携分析
    Summary Bukwang PharmCo Ltd (BUKWANG) is a pharmaceutical company which develops pharmaceutical products and new drugs. The company’s product portfolio includes levovir, legalon, dexid, thioctacid, lonasen, ixel, Orfil, azeptin, asima among others. Its pipeline products comprise MLR-1023, JM-010, JM …
  • Ra Pharmaceuticals Inc (RARX):製薬・医療:M&Aディール及び事業提携情報
    Summary Ra Pharmaceuticals Inc (Ra Pharmaceuticals) is a clinical stage biopharmaceutical company that develops therapeutics for the treatment of diseases caused due to uncontrolled activation of the complement system. Ra Pharmaceuticals develops its pipeline products through its proprietary peptide …
  • Rousselot S.A.S.:企業の戦略・SWOT・財務情報
    Rousselot S.A.S. - Strategy, SWOT and Corporate Finance Report Summary Rousselot S.A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Koninklijke Philips N.V. (PHIA):電力:M&Aディール及び事業提携情報
    Summary Koninklijke Philips N.V. (Philips) is a diversified technology company develops and manufactures medical systems, consumer electronics and lighting products. The company offers patient care & clinical informatics, imaging systems, healthcare transformation services and home healthcare soluti …
  • The Taiko Bank Ltd:企業の戦略・SWOT・財務情報
    The Taiko Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Taiko Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Entera Bio Ltd (ENTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Entera Bio Ltd (Entera Bio) is a clinical-stage biopharmaceutical company that provides development and commercialization of a novel drug delivery platform for bone healing. The company develops novel drug delivery platform for oral delivery of large molecule protein active pharmaceutical in …
  • SM Energy Company:企業のM&A・事業提携・投資動向
    SM Energy Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's SM Energy Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Nature’s Sunshine Products Inc (NATR):企業の財務・戦略的SWOT分析
    Summary Nature's Sunshine Products Inc (Nature's Sunshine) is a manufacturer and marketer of nutritional and personal care products. The company’s products comprise daily essential pack, probiotics, antioxidants, enzymes, vitamins and minerals, general cleansers, fiber, meal replacement and protein, …
  • Koki Holdings Co Ltd:企業の戦略的SWOT分析
    Koki Holdings Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Premaitha Health Plc (NIPT):製薬・医療:M&Aディール及び事業提携情報
    Summary Premaitha Health Plc (Premaitha Health), formerly Vialogy Plc, is a molecular diagnostics company, which focuses on the development of genetic screening tests including novel tests for non-invasive prenatal screening (NIPT). Its flagship product, the IONA test is an advanced NIPT test that a …
  • Ascentage Pharma Group Corp Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Ascentage Pharma Group Corp Ltd (Ascentage Pharma) is a biopharmaceutical company that discovers and develops targeted small-molecule therapeutics for the treatment of cancers, hepatitis B and age-related diseases. The company’s pipeline product includes apoptosis compounds and kinase inhibi …
  • Alterity Therapeutics Ltd (PBT):企業の財務・戦略的SWOT分析
    Summary Alterity Therapeutics Ltd (Alterity Therapeutics) formerly known as Prana Biotechnology Ltd, is a developer of therapeutic drugs. The company is conducting research into Huntington disease, Alzheimer's disease, brain cancer and other major age-related degenerative disorders. It is developing …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆